Medical societies to launch large-scale study on vein filter use

Monday, February 4, 2013 11:56 AM

The Society of Interventional Radiology (SIR) and Society for Vascular Surgery (SVS) jointly will launch PRESERVE—the first large-scale, multi-specialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

The study, along with the formation of the IVC Filter Study Group Foundation, are direct actions taken to address the August 2010 FDA medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients.

SIR and SVS are in the process of determining a framework for the PRESERVE (PREdicting the Safety and Effectiveness of InferioR VEna Cava Filters) study, with the goal of obtaining a functional view of all filters placed in the U.S.

"PRESERVE data will allow a systematic, functional view, representative of all filters placed in the U.S., thus, all stakeholders—individuals, health care professionals, insurers and government regulators—will be armed with the knowledge they need on patient risk and, subsequently, quality improvement in filter placement, management and retrieval," said Marshall E. Hicks, M.D., FSIR, president of SIR.

Peter Gloviczki, M.D., president of SVS, added, “This is a paradigm-shifting initiative: interventional radiologists and vascular surgeons collaborating to launch a large-scale prospective study evaluating inferior vena cava filters reveals a lot about each specialty's focus--and that focus is on patients, first and foremost.”

The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 1,800 patients at approximately 50 centers in the U.S. Members of the IVC Filter Study Group Foundation collectively discussed ways to respond to the FDA's stated concerns. SIR and SVS are in the process of making a final decision for a CRO, completing protocol development and submitting the study for investigational device exemption study with HIPAA compliance.

Study directors are Matthew S. Johnson, M.D., FSIR, Indiana University School of Medicine, and David L. Gillespie M.D., FACS, University of Rochester School of Medicine and Dentistry. Most filter manufacturers have agreed to participate in the study.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs